Factor VIII biosimilar (Chia Tai-Tianqing)

人凝血因子VIII生物类似药 (正大天晴)

Report date: 2026/05/20 20:02:01

Base Information

Drug NameFactor VIII biosimilar (Chia Tai-Tianqing)
Drug Alias NameRecombinant Human Coagulation Factor VIII (Nanjing Shunxin Pharmaceuticals)人凝血因子VIII生物仿制药 (Alphamab)重组人凝血因子Ⅷ安恒吉KN-008 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factorBiologics > Biosimilar
Mechanisms of ActionCoagulation factor X stimulantsBlood coagulation pathway activationCoagulation factor VIII replacements
TargetsCoagulation factor XCoagulation factor VIII
Therapy Area/IndicationsHemophilia A
Global Approved IndicationsHemophilia A
Approved Indications in ChinaHemophilia A
Original Approved Country/TerritoryMainland China
Original Approved Date2023/08/29
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSuzhou Alphamab Co LtdJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
Inactive CompaniesJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Active IndicationsHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeB02BD02
Related LinksN/A